Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2017.164 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis |
Dr. HUI Aric Josun 許祖紳 |
| 2017.165 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) |
Dr. HUI Aric Josun 許祖紳 |
| 2017.531 | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment |
Dr. HUI Aric Josun 許祖紳醫生 |
| 2014.610 | A Risk Score derived from a large Gastrointestinal Bleeding Registry with Retrospective Validation | Dr. HUI Aric Josun |
| 2014.591 | A Phase IIB-III, open-label, randomized, comparative study to assess the efficacy of ABX203 to maintain control of Hepatitis B disease after cessation of treatment with nucleos(t)ide analogs in adult HBeAg negative patients with chronic Hepatitis B in the Asia Pacific region | Dr. HUI Aric Josun |
| 2015.585 | The Hong Kong HCV Registry |
Dr. HUI Aric Josun 許祖紳 |
| 2011.591 | Serum hepatitis B surface antigen levels to guide the stopping of entecavir in HbeAg-negative chronic hepatitis B | Dr Hui Aric Josun |
| 2013.434 | Predictors of Colonoscopy Non-attendance and the Efficacy of a Short Message Service (SMS) Reminder to reduce Non-attendance Rate: A Prospective Randomized Controlled Trial (NAC Study) | Dr. HUI Aric Josun |
| 2013.250 | Clinical Outcomes of Patients with Obscure-Overt Gastrointestinal Bleeding: Analysis of a 13 year Gastrointestinal Bleed Registry | Dr. HUI Aric Josun |
| 2012.421 | Double Balloon Enteroscopy in Hong Kong: Six years experience at a Single Center | DR HUI ARIC JOSUN |
| 2009.247 | A Single-arm, Multinational, Two Year Study Evaluating the Efficacy and Safety of Lead-in Telbivudine for 24 Weeks with or without Tenofovir Treatment Intensification in Adult patients with HBeAg-positive Chronic Hepatitis B | Dr Hui Aric Josun |
| 2020.012 | Spousal coordination across transition to parenthood: Its associations with physical and psychological well-being |
Dr. HUI Chin Ming 許展明 |
| 2019.067 | The influence of emotion regulation on physiological changes in couple conflict discussion |
Dr. HUI Chin Ming 許展明 |
| 2019.066 | Spousal coordination across transition to parenthood: Its prenatal antecedents and links with health and relationship well-being |
Dr. HUI Chin Ming 許展明 |
| 2009.451 | A Pilot Phase 2, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult Hospitalized Subjects with Confirmed Pandemic H1N1 Influenza Infection | Prof Hui David |
| 2014.345 | Obstructive sleep apnoea and CPAP treatment response in patients with non-alcoholic fatty liver disease | Prof. HUI David S.C. |
| 2011.005 | Validation of the new COPD Assessment Test (CAT) translated into Chinese in patients with Chronic Obstructuve Pulmonary Disease (COPD) | Prof Hui David SC Hui |
| 2011.312 | Ethnic and Gender Comparison of Craniofacial Phenotypes in Obstructive Sleep Apnoea | Prof Hui David SC Hui |
| 2011.215 | A randomized controlled study assessing the role of an ambulatory approach versus the conventional approach in managing moderate to severe obstructive sleep apnoea syndrome | Prof Hui David Shu Cheong |
| 2010.267 | A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety and immunogenicity of GSK Biologicals’ gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 70 years and older | Prof. HUI David Shu Cheong |
| 2010.266 | A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 50 years and older | Prof. HUI David Shu Cheong |
| 2010.605 | A 6-month, double-blind, randomised, multicenter, multinational trial to investigate the effect of 500 | Professor Hui David Shu Cheong |
| 2013.213 | A 52-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD | Prof. HUI David Shu Cheong |
| 2011.470 | A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared with Aclidinium Bromide, Formoterol Fumarate and Placebo for 24 Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD) | Professor Hui David Shu Cheong |
| 2008.286 | A Randomized, Parallel, Controlled Study to Evaluate the Role of Pretreatment Drug Susceptibility Tests in the Selection of Regimens of Chemotherapy for Retreatment of Relapsed Pulmonary TB in Guangzhou | Prof Hui David Shu Cheong |
| 2016.191 | A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogenicity persistence of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine and assessment of 1 or 2 additional doses on a 0 or 0, 2-month schedule in two subgroups of older adults. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2014.334 | Randomized, double-blind, placebo-controlled, multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non-cystic fibrosis bronchiectasis | Prof. HUI David Shu Cheong |
| 2017.238 | A prospective, epidemiological, multi-country, cohort study to assess the occurrence of potential bacterial and viral pathogens in stable chronic obstructive pulmonary disease (COPD) and during acute exacerbations of COPD (AECOPD), in moderate to very severe COPD patients, in Asia Pacific. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2014.640 | A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe to very severe COPD. | Prof. HUI David Shu Cheong |
| 2014.417 | A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease | Prof. HUI David Shu Cheong |
| 2014.319 | An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccine(s) GSK3277510A and GSK3277509A administered in adults 18 to 60 years of age. | Prof. HUI David Shu Cheong |
| 2016.096 | A Phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine when administered intramuscularly on a two-dose schedule to subjects who previously received placebo in ZOSTER-006 and ZOSTER-022 studies. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2021.298 | Prevalence of non-alcoholic fatty liver disease among non-obese obstructive sleep apnea by using transient elastography | Prof. HUI David Shu Cheong |
| 2022.412 | Study on Clinical Use of EVUSHELD (AZD7442) in the Real-world Setting – A Multicentre, Single-arm, Observational Study to Determine the Utilisation and Clinical Outcomes of EVUSHELD in China |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2021.032 | A PHASE III OPEN LABEL EXTENSION STUDY TO EVALUATE LONG TERM SAFETY AND EFFICACY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2023.628 | Long-term longitudinal comparisons of health status and immune responses in elderly cohorts with seasonal influenza vaccine in Hong Kong | Prof. HUI David Shu Cheong |
| 2022.407 | A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow- up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of immune response of a Herpes Zoster subunit vaccine and assessment of persistence of immune response and safety of 1 or 2 additional doses administered in ZOSTER-049 in 2 subgroups of older adults. | Prof. HUI David Shu Cheong |
| 2024.428 | The disease burden of RSV infection in Hong Kong | Prof. HUI David Shu Cheong |
| 2024.240 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | Prof. HUI David Shu Cheong |
| 2024.481 | SA-BioPercept study: A survey study on biologics initiation from the perspective of moderate-tosevere asthma patients | Prof. HUI David Shu Cheong |
| 2024.207 | A study to evaluate the consistency of oscillometry and spirometry test results in patients with confirmed or suspected asthma or COPD |
Prof. Hui David Shu Cheong 許樹昌 |
| 2011.214 | The effects of CPAP on twist mechanics of the left ventricle in patients with moderate to severe Obstructive Sleep Apnoea | Prof Hui David Shu Cheong |
| 2007.072 | Management and Clinical Progress of Patients with Severe Influenza - A Prospective Observational Study | Prof. HUI David Shu Cheong |
| 2019.392 | A phase III, randomized, observer-blind, placebo controlled, multicenter clinical trial to assess Herpes Zoster recurrence and the reactogenicity, safety and immunogenicity of GSK Biologicals’ Herpes Zoster vaccine (HZ/su) when administered intramuscularly on a 0 and 2 month schedule to adults ≥ 50 years of age with a prior episode of Herpes Zoster. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2018.433 | A PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL IN COMBINATION WITH STANDARD-OF-CARE NEURAMINIDASE INHIBITOR IN HOSPITALIZED PATIENTS WITH SEVERE INFLUENZA |
Prof. HUI David Shu Cheong 許樹昌 |
| 2019.634 | Screening for lung cancer in subjects with family history of lung cancer. |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2018.613 | A randomized, double blind, placebo controlled trial of intravenous N-acetylcysteine and oseltamivir versus intravenous 5% dextrose and oseltamivir alone in adults hospitalized with influenza complicated by lower respiratory tract infection |
Prof. HUI David Shu Cheong 許樹昌 |
| 2018.250 | Observational study to assess frailty of subjects during ZOSTER-006 and ZOSTER-022 and HZ efficacy, immunogenicity and safety of HZ/su by frailty status. | Prof. HUI David Shu Cheong |
| 2020.229 | Long-term longitudinal comparisons of health and immunity status in convalescent COVID-19 and vaccinated cohorts in Hong Kong |
Prof. HUI David Shu Cheong 許樹昌 |
| 2020.220 | Tropism and pathogenesis of SARS-CoV-2 in human macrophages |
Prof. HUI David Shu Cheong 許樹昌 |
Page 102 of 254.